XSHE
000788
Market cap487mUSD
Oct 09, Last price
5.67CNY
1D
3.47%
1Q
8.41%
Jan 2017
-60.10%
Name
PKU HealthCare Corp Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating within China, PKU HealthCare Corp.,Ltd. is a pharmaceutical company that specializes in the research, development, manufacturing, and distribution of medicinal products. Its extensive portfolio encompasses a broad spectrum of therapeutic areas, offering medications for conditions such as cancer (anti-tumor, oncology), neuropsychiatric disorders, cardiovascular issues, immune system regulation (immunosuppressive), infections (antimicrobial), pain and fever (antipyretic and analgesic), digestive ailments, allergies, blood sugar management, mental health, and blood volume expansion. Founded in 1965, the company was initially known as PUK International Hospital Group Southwest Synthetic Pharmaceutical Corp., Ltd. before officially rebranding to PKU HealthCare Corp.,Ltd. in November 2013. Its primary operations are based out of its headquarters in Chongqing, China.
Key people
Acting Chairman of the Board · since 2025
Xiren Xu
Chairman of the Board · since 2025
Mengchuan Yu
Acting President, Executive Vice President · since 2025
Quanbo Zhao
Chief Financial Officer, Vice President · since 2024
Xianghong Chen
Vice President · since 2024
Qingkai He
Vice President · since 2024
Yufei Yuan
Secretary of the Board · since 2024
Tiemin Bao
Director · since 2025
Lianjun Huang
Director · since 2025
Jianfei Jia
Director · since 2024
Lijin Yang
Director · since 2025
Independent Director · since 2024
Weining Wang
Independent Director · since 2024
Jianguang Zeng
Independent Director · since 2024
Headquarters & legal address
重庆市北碚区水土镇方正大道21号
北碚区, CQ 400000
CN
北碚区, CQ 400000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||